Brightgene Bio-medical Technology Co. Ltd. Class ASSE: 688166

"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss Indication

Aug 7, 2026 · Issued by Brightgene Bio-medical Technology Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of the Phase I Clinical Trial Data of BGM1812 Injection for Weight Loss Indication

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Brightgene Bio-medical Technology Co. Ltd. Class A

"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide Inhalation Spray by a Controlled SubsidiaryAug 1
"Brightgene Bio-Medical Technology Co., Ltd."Voluntary Disclosure Announcement on Acquisition of Drug Registration Certificate for Tiotropium Bromide and Olodaterol Inhalation Spray by a Controlled SubsidiaryJul 25
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on the Board Secretary's Obtaining the Certificate of Qualification Training and Officially Assuming DutiesJul 24
"Brightgene Bio-Medical Technology Co., Ltd."Announcement on Appointment of Secretary of the Board of DirectorsJul 21

All Brightgene Bio-medical Technology Co. Ltd. Class A news releases